Antifungal resistance poses a significant clinical challenge for treating invasive fungal infections. Candida albicans is responsible for candidiasis including invasive fungal infections, where most patients are immunocompromised. Therefore the success of treatment depends significantly on the effectiveness of the antifungal agent. In this study, sixteen novel furan derivatives containing the azetidinone moiety were designed and synthesized to arrive at potentially effective antifungal agents. In silico antifungal activity was carried out to identify the specificity of the novel furan derivatives for the fungal proteins using 'Glide'. Molecular docking studies were conducted on two antifungal targets; Dihydrofolate reductase of C.albicans (PDB ID: 4HOE); N-myristoyl transferase of C.albicans (PDB ID: 1IYK). Molecular docking was carried out at the Standard Precision (SP) and Extra Precision (XP) mode. The docked poses were ranked according to their docking scores (GScore) and their binding energy with the enzyme. The results obtained for the docking of the title compounds with N-myristoyl transferase of C.albicans is quite promising. Molecular docking suggests that compounds 4d, 4e, and 4h are potential inhibitors of N-myristoyl transferase and are specific in binding at the active site of the enzyme. They form Hbond with THR 211 and pi-pi stacking interactions with PHE 117, TRY 354, and TRY 225 at the active site of the protein, similar to the standard drug. However the test compounds show low docking scores against Dihydrofolate reductase of C.albicans indicating that they may not be effective against it.